Immatics (IMTX) Stock Forecast, Price Target & Predictions
IMTX Stock Forecast
Immatics stock forecast is as follows: an average price target of $22.00 (represents a 135.29% upside from IMTX’s last price of $9.35) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
IMTX Price Target
The average price target for Immatics (IMTX) is $22.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $16.00. This represents a potential 135.29% upside from IMTX's last price of $9.35.
IMTX Analyst Ratings
According to 1 Wall Street analysts, Immatics's rating consensus is 'Buy'. The analyst rating breakdown for IMTX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Immatics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 16, 2024 | Graig Suvannavejh | Mizuho Securities | $16.00 | $11.08 | 44.40% | 71.12% |
| Aug 09, 2022 | Geulah Livshits | Chardan Capital | $28.00 | $12.43 | 125.26% | 199.47% |
The latest Immatics stock forecast, released on May 16, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $16.00, which represents a 44.40% increase from the stock price at the time of the forecast ($11.08), and a 71.12% increase from IMTX last price ($9.35).
Immatics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $16.00 |
| Last Closing Price | $9.35 | $9.35 | $9.35 |
| Upside/Downside | -100.00% | -100.00% | 71.12% |
In the current month, the average price target of Immatics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immatics's last price of $9.35. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 07, 2024 | Piper Sandler | - | Overweight | Initialise |
Immatics's last stock rating was published by Piper Sandler on Oct 07, 2024. The company Initialise its IMTX rating from "null" to "Overweight".
Immatics Financial Forecast
Immatics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $9.80M | $37.65M | $15.06M | $17.21M | $102.91M | $15.73M | $6.44M | $5.19M | $7.40M | $9.45M | $6.90M |
| Avg Forecast | $14.92M | $14.92M | $18.94M | $18.49M | $15.59M | $15.86M | $13.40M | $20.53M | $13.83M | $10.92M | $20.43M | $11.91M | $23.55M | $162.16M | $10.27M | $10.79M | $8.83M | $8.59M | $7.83M | $7.30M | $5.75M | $6.36M |
| High Forecast | $14.92M | $14.92M | $18.94M | $18.49M | $15.59M | $19.85M | $13.84M | $21.28M | $21.17M | $11.10M | $20.43M | $11.91M | $23.55M | $162.16M | $10.27M | $10.79M | $8.83M | $8.59M | $7.83M | $7.30M | $5.75M | $7.65M |
| Low Forecast | $14.92M | $14.92M | $18.94M | $18.49M | $15.59M | $12.49M | $12.95M | $19.78M | $6.49M | $10.73M | $20.43M | $11.91M | $23.55M | $162.16M | $10.27M | $10.79M | $8.83M | $8.59M | $7.83M | $7.30M | $5.75M | $4.07M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 4 | 4 | 4 | 4 | 4 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.82% | 1.60% | 0.09% | 1.68% | 9.54% | 1.78% | 0.75% | 0.66% | 1.01% | 1.64% | 1.08% |
Immatics's average Quarter revenue forecast for Jun 23 based on 2 analysts is $20.43M, with a low forecast of $20.43M, and a high forecast of $20.43M. IMTX's average Quarter revenue forecast represents a 108.59% increase compared to the company's last Quarter revenue of $9.80M (Mar 23).
Immatics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 4 | 4 | 4 | 4 | 4 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-22.36M | $10.46M | $-19.44M | $-14.82M | $70.13M | $-15.33M | $-25.34M | $-22.50M | $-20.40M | $-21.53M | $-17.64M |
| Avg Forecast | $-11.13M | $-11.13M | $-14.13M | $-13.80M | $-11.63M | $-11.84M | $-10.00M | $-15.32M | $-10.32M | $-8.15M | $-15.25M | $-8.89M | $-17.58M | $-121.03M | $-7.66M | $-8.05M | $-6.59M | $-6.41M | $-5.84M | $-5.45M | $-4.29M | $-4.75M |
| High Forecast | $-11.13M | $-11.13M | $-14.13M | $-13.80M | $-11.63M | $-9.32M | $-9.67M | $-14.76M | $-4.85M | $-8.01M | $-15.25M | $-8.89M | $-17.58M | $-121.03M | $-7.66M | $-8.05M | $-6.59M | $-6.41M | $-5.84M | $-5.45M | $-4.29M | $-3.04M |
| Low Forecast | $-11.13M | $-11.13M | $-14.13M | $-13.80M | $-11.63M | $-14.82M | $-10.33M | $-15.89M | $-15.80M | $-8.28M | $-15.25M | $-8.89M | $-17.58M | $-121.03M | $-7.66M | $-8.05M | $-6.59M | $-6.41M | $-5.84M | $-5.45M | $-4.29M | $-5.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 2.52% | -0.60% | 0.16% | 1.93% | -8.71% | 2.33% | 3.96% | 3.85% | 3.74% | 5.02% | 3.72% |
2 analysts predict IMTX's average Quarter EBITDA for Mar 23 to be $-8.89M, with a high of $-8.89M and a low of $-8.89M. This is -184.93% lower than Immatics's previous annual EBITDA (Dec 22) of $10.46M.
Immatics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 4 | 4 | 4 | 4 | 4 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-15.12M | $-13.26M | $-20.93M | $-13.98M | $85.66M | $-17.51M | $-31.41M | $-24.23M | $-19.36M | $-25.15M | $-22.77M |
| Avg Forecast | $-30.75M | $-30.75M | $-27.67M | $-25.62M | $-32.51M | $-25.77M | $-29.05M | $-21.13M | $-33.06M | $-37.35M | $-25.36M | $-27.91M | $-7.70M | $206.11M | $-39.19M | $-32.61M | $-35.85M | $-32.87M | $-33.21M | $-26.96M | $-16.38M | $-15.57M |
| High Forecast | $-30.75M | $-30.75M | $-27.67M | $-25.62M | $-32.51M | $-21.00M | $-29.05M | $-21.13M | $-26.61M | $-37.35M | $-25.36M | $-27.91M | $-7.70M | $206.11M | $-39.19M | $-32.61M | $-35.85M | $-32.87M | $-33.21M | $-26.96M | $-16.38M | $-13.74M |
| Low Forecast | $-30.75M | $-30.75M | $-27.67M | $-25.62M | $-32.51M | $-35.32M | $-29.05M | $-21.13M | $-38.70M | $-37.35M | $-25.36M | $-27.91M | $-7.70M | $206.11M | $-39.19M | $-32.61M | $-35.85M | $-32.87M | $-33.21M | $-26.96M | $-16.38M | $-19.23M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.54% | 1.72% | -0.10% | 0.36% | -2.63% | 0.49% | 0.96% | 0.73% | 0.72% | 1.54% | 1.46% |
Immatics's average Quarter net income forecast for Jun 22 is $-39.19M, with a range of $-39.19M to $-39.19M. IMTX's average Quarter net income forecast represents a -145.75% decrease compared to the company's last Quarter net income of $85.66M (Mar 22).
Immatics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 4 | 4 | 4 | 4 | 4 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $9.59M | $9.74M | $8.42M | $8.68M | $9.28M | $8.84M | $8.27M | $8.27M | $8.43M | $8.70M | $10.08M |
| Avg Forecast | $10.80M | $10.80M | $13.71M | $13.38M | $11.29M | $11.48M | $9.70M | $14.86M | $10.01M | $7.90M | $14.79M | $8.62M | $17.05M | $117.40M | $7.43M | $7.81M | $6.39M | $6.22M | $5.67M | $5.29M | $4.16M | $4.61M |
| High Forecast | $10.80M | $10.80M | $13.71M | $13.38M | $11.29M | $14.37M | $10.02M | $15.41M | $15.33M | $8.04M | $14.79M | $8.62M | $17.05M | $117.40M | $7.43M | $7.81M | $6.39M | $6.22M | $5.67M | $5.29M | $4.16M | $5.54M |
| Low Forecast | $10.80M | $10.80M | $13.71M | $13.38M | $11.29M | $9.04M | $9.38M | $14.32M | $4.70M | $7.77M | $14.79M | $8.62M | $17.05M | $117.40M | $7.43M | $7.81M | $6.39M | $6.22M | $5.67M | $5.29M | $4.16M | $2.95M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.11% | 0.57% | 0.07% | 1.17% | 1.19% | 1.38% | 1.33% | 1.46% | 1.60% | 2.09% | 2.19% |
Immatics's average Quarter SG&A projection for Jun 23 is $14.79M, based on 2 Wall Street analysts, with a range of $14.79M to $14.79M. The forecast indicates a 54.33% rise compared to IMTX last annual SG&A of $9.59M (Mar 23).
Immatics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 4 | 4 | 4 | 4 | 4 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.20 | $-0.20 | $-0.32 | $-0.22 | $1.36 | $-0.28 | $-0.50 | $-0.39 | $-0.31 | $-0.40 | $-0.36 |
| Avg Forecast | $-0.30 | $-0.30 | $-0.27 | $-0.25 | $-0.32 | $-0.25 | $-0.28 | $-0.20 | $-0.32 | $-0.36 | $-0.25 | $-0.27 | $-0.07 | $2.00 | $-0.38 | $-0.32 | $-0.35 | $-0.32 | $-0.32 | $-0.26 | $-0.16 | $-0.15 |
| High Forecast | $-0.30 | $-0.30 | $-0.27 | $-0.25 | $-0.32 | $-0.20 | $-0.28 | $-0.20 | $-0.26 | $-0.36 | $-0.25 | $-0.27 | $-0.07 | $2.00 | $-0.38 | $-0.32 | $-0.35 | $-0.32 | $-0.32 | $-0.26 | $-0.16 | $-0.13 |
| Low Forecast | $-0.30 | $-0.30 | $-0.27 | $-0.25 | $-0.32 | $-0.34 | $-0.28 | $-0.20 | $-0.38 | $-0.36 | $-0.25 | $-0.27 | $-0.07 | $2.00 | $-0.38 | $-0.32 | $-0.35 | $-0.32 | $-0.32 | $-0.26 | $-0.16 | $-0.19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.74% | 2.68% | -0.16% | 0.58% | -4.30% | 0.81% | 1.57% | 1.21% | 1.18% | 2.52% | 2.38% |
According to 1 Wall Street analysts, Immatics's projected average Quarter EPS for Jun 22 is $-0.38, with a low estimate of $-0.38 and a high estimate of $-0.38. This represents a -127.96% decrease compared to IMTX previous annual EPS of $1.36 (Mar 22).
Immatics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ALXO | ALX Oncology | $1.49 | $24.50 | 1544.30% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| LYEL | Lyell Immunopharma | $1.27 | $6.67 | 425.20% | Hold |
| AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
| FENC | Fennec Pharmaceuticals | $4.65 | $15.75 | 238.71% | Buy |
| BCAB | BioAtla | $2.00 | $5.00 | 150.00% | Buy |
| IMTX | Immatics | $9.35 | $22.00 | 135.29% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| REPL | Replimune Group | $12.02 | $24.20 | 101.33% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
| KROS | Keros Therapeutics | $59.95 | $102.00 | 70.14% | Buy |
| MRUS | Merus | $51.23 | $77.13 | 50.56% | Buy |
| HRMY | Harmony Biosciences | $33.05 | $48.86 | 47.84% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.82 | $70.14 | 23.44% | Buy |
| JANX | Janux Therapeutics | $55.87 | $61.20 | 9.54% | Buy |
IMTX Forecast FAQ
Is Immatics a good buy?
Yes, according to 1 Wall Street analysts, Immatics (IMTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of IMTX's total ratings.
What is IMTX's price target?
Immatics (IMTX) average price target is $22 with a range of $16 to $28, implying a 135.29% from its last price of $9.35. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Immatics stock go up soon?
According to Wall Street analysts' prediction for IMTX stock, the company can go up by 135.29% (from the last price of $9.35 to the average price target of $22), up by 199.47% based on the highest stock price target, and up by 71.12% based on the lowest stock price target.
Can Immatics stock reach $14?
IMTX's average twelve months analyst stock price target of $22 supports the claim that Immatics can reach $14 in the near future.
What are Immatics's analysts' financial forecasts?
Immatics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $65.37M (high $70.57M, low $60.81M), average EBITDA is $-48.794M (high $-45.386M, low $-52.668M), average net income is $-108M (high $-104M, low $-118M), average SG&A $47.33M (high $51.09M, low $44.03M), and average EPS is $-1.052 (high $-1.006, low $-1.145). IMTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $67.26M (high $67.26M, low $67.26M), average EBITDA is $-50.199M (high $-50.199M, low $-50.199M), average net income is $-115M (high $-115M, low $-115M), average SG&A $48.69M (high $48.69M, low $48.69M), and average EPS is $-1.114 (high $-1.114, low $-1.114).
Did the IMTX's actual financial results beat the analysts' financial forecasts?
Based on Immatics's last annual report (Dec 2022), the company's revenue was $172.83M, which missed the average analysts forecast of $206.76M by -16.41%. Apple's EBITDA was $46.34M, missing the average prediction of $-154M by -130.03%. The company's net income was $37.51M, missing the average estimation of $126.62M by -70.37%. Apple's SG&A was $36.12M, missing the average forecast of $149.7M by -75.87%. Lastly, the company's EPS was $0.56, missing the average prediction of $1.23 by -54.41%. In terms of the last quarterly report (Mar 2023), Immatics's revenue was $9.8M, missing the average analysts' forecast of $11.91M by -17.74%. The company's EBITDA was $-22.365M, beating the average prediction of $-8.888M by 151.63%. Immatics's net income was $-15.123M, missing the average estimation of $-27.907M by -45.81%. The company's SG&A was $9.59M, beating the average forecast of $8.62M by 11.18%. Lastly, the company's EPS was $-0.2, missing the average prediction of $-0.271 by -26.13%